PuraPharm Corp. Ltd. (HK:1498) has released an update.
PuraPharm Corporation Limited anticipates a significant decrease in its net loss to not more than HK$20 million for the first half of 2024, a substantial improvement from the HK$37.7 million loss in the same period of 2023. This improvement is largely due to reduced fair value loss of biological assets and effective cost control measures. Investors are advised to exercise caution and await the finalized interim results expected by the end of August 2024.
For further insights into HK:1498 stock, check out TipRanks’ Stock Analysis page.
